Navigation Links
Selexis SA to Present and Partner at the BIO-Europe 2013 Partnering Conference
Date:10/24/2013

Geneva, Switzerland (PRWEB) October 24, 2013

Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the Company’s president and CEO, Igor Fish, Ph.D., will present, “Selexis SURE CHO-Mplus™ Libraries: Custom Solutions for Improved Recombinant Protein Production” on Tuesday, November 5 at 4:45 PM at the BIO-Europe 2013 Partnering Conference being held November 4 – 6, at the Messe Wien Exhibition and Congress Center in Vienna, Austria. The Company will be also taking part in the pre-scheduled partnering meetings.

Presentation Abstract:
Stable, high-level production of recombinant proteins requires not only elevated transcription, but also cellular systems that can accommodate all of the protein folding, metabolic, secretory transport and post-translational processing requirements of any given protein. These requirements can vary significantly from protein to protein. Leveraging data from the completed SURE CHO-M Genome and Transciptome, Selexis has engineered the SURE CHO-Mplus libraries to address expression issues such as stalled translocation, improper folding, incomplete post-translational modifications, chromosomal instability or insufficient cellular respiration. With these libraries, Selexis has been able to significantly boost expression over broad range of proteins, including large multimeric structural proteins and and difficult to express proteins.

Companies or individuals attending BIO-Europe can schedule meetings with Selexis (registration required) by visiting: http://www.ebdgroup.com/bioeurope/index.php

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

# # #

Read the full story at http://www.prweb.com/releases/selexis_bio_europe/protiens_antibodies/prweb11264432.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Selexis SA Announces Publication in Metabolic Engineering of Data Demonstrating Improvement of Therapeutic Protein Secretion with Engineered CHO Cells
2. Selexis SA to Present and Partner at the BIO-Europe Spring
3. Selexis SA to Partner and Exhibit at BIO 2013
4. Selexis SA Launches SURE CHO-Mplus™ Libraries
5. Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering
6. Advancement in Biologic Protein Expression Webinar Hosted by Selexis SA
7. Selexis SA to Present Data on Improved Selection of Recombinant Protein Production Clones at the Bioprocessing Summit 2013
8. Targeted therapeutics for colon cancer to be presented at AACR meeting
9. NYU Langone experts present research, clinical advances at neurosurgeons meeting
10. Specific inhibition of autophagy may represent a new concept for treatment of kidney cancer
11. Presidential Recognition Awards presented during the 2012 AIUM Annual Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
(Date:6/24/2016)... ... , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event ... that have been wounded in battle and their families. Venture Construction Group is a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
Breaking Medicine Technology: